Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.400 Biomarker group BEFREE These characteristics indicate a potential role for RASSF1A as a lung tumour suppressor gene. 10888881 2000
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. 10998413 2000
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.400 Biomarker group BEFREE The human Ras association domain family 1A gene (RASSF1A), recently cloned from the lung tumor suppressor locus 3p21.3, was shown to be hypermethylated in primary lung tumors, and reexpression of RASSF1A suppressed the growth of lung cancer cells (R. Dammann et al., Nat.Genet., 25: 315-319, 2000). 11306494 2001
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 PosttranslationalModification disease BEFREE The data suggest that hypermethylation of the CpG island promoter of RASSF1A may play an important role in breast cancer pathogenesis. 11306494 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Coincident with methylation, the expression level of RASSF1A was lower in tumors compared with matching normal tissues. 11306494 2001
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 PosttranslationalModification disease BEFREE The data suggest that hypermethylation of the CpG island promoter of RASSF1A may play an important role in breast cancer pathogenesis. 11306494 2001
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.400 GeneticVariation disease BEFREE Twenty of 26 SCLC tumours with 3p21.3 allelic loss had RASSF1A methylation, while only six out of 22 NSCLC with 3p21.3 allele loss had RASSF1A methylation (P=0.0012), one out of five ovarian and none out of six cervical tumours with 3p21.3 loss had RASSF1A methylation. 11313894 2001
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.400 Biomarker group BEFREE To investigate RASSF1A as a candidate TSG for various cancers, we investigated: (a) RASSF1A methylation status in a large series of primary tumour and tumour lines; (b) chromosome 3p allele loss in lung tumours and (c) RASSF1 mutation analysis in breast tumours. 11313894 2001
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 PosttranslationalModification disease BEFREE In view of the lower frequency of RASSF1 methylation in primary breast cancers we proceeded to RASSF1 mutation analysis in 40 breast cancers. 11313894 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE To investigate RASSF1A as a candidate TSG for various cancers, we investigated: (a) RASSF1A methylation status in a large series of primary tumour and tumour lines; (b) chromosome 3p allele loss in lung tumours and (c) RASSF1 mutation analysis in breast tumours. 11313894 2001
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.100 PosttranslationalModification disease BEFREE Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. 11313894 2001
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 GeneticVariation group BEFREE To investigate RASSF1A as a candidate TSG for various cancers, we investigated: (a) RASSF1A methylation status in a large series of primary tumour and tumour lines; (b) chromosome 3p allele loss in lung tumours and (c) RASSF1 mutation analysis in breast tumours. 11313894 2001
CUI: C4048328
Disease: cervical cancer
cervical cancer 		0.090 AlteredExpression disease BEFREE These results suggest that (a) RASSF1A inactivation by two hits (methylation and loss) is a critical step in SCLC tumourigenesis and (b) RASSF1A inactivation is of lesser importance in NSCLC, breast, ovarian and cervical cancers in which other genes within LCTSGR1 are likely to be implicated. 11313894 2001
CUI: C0149925
Disease: Small cell carcinoma of lung
Small cell carcinoma of lung 		0.070 Biomarker disease BEFREE These results suggest that (a) RASSF1A inactivation by two hits (methylation and loss) is a critical step in SCLC tumourigenesis and (b) RASSF1A inactivation is of lesser importance in NSCLC, breast, ovarian and cervical cancers in which other genes within LCTSGR1 are likely to be implicated. 11313894 2001
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.400 PosttranslationalModification disease BEFREE RASSF1A promoter hypermethylation in resected NSCLCs was associated with impaired patient survival (P =.046). 11333291 2001
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.400 AlteredExpression disease BEFREE We also transfected a lung cancer cell line that lacks RASSF1A expression with vectors containing RASSF1A complementary DNA to determine whether exogenous expression of RASSF1A would affect in vitro growth and in vivo tumorigenicity of this cell line.All statistical tests were two-sided. 11333291 2001
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 PosttranslationalModification disease BEFREE RASSF1A promoter hypermethylation was detected in 100% of SCLC, in 63% of NSCLC, in 64% of breast cancer lines, in 30% of primary NSCLCs, and in 49% of primary breast tumors but in none of the nonmalignant lung tissues. 11333291 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE We explored the hypothesis that RASSF1 encodes a tumor suppressor gene for lung and breast cancers. 11333291 2001
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 PosttranslationalModification disease BEFREE RASSF1A promoter hypermethylation was detected in 100% of SCLC, in 63% of NSCLC, in 64% of breast cancer lines, in 30% of primary NSCLCs, and in 49% of primary breast tumors but in none of the nonmalignant lung tissues. 11333291 2001
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.100 AlteredExpression disease BEFREE We also transfected a lung cancer cell line that lacks RASSF1A expression with vectors containing RASSF1A complementary DNA to determine whether exogenous expression of RASSF1A would affect in vitro growth and in vivo tumorigenicity of this cell line.All statistical tests were two-sided. 11333291 2001
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.100 AlteredExpression disease BEFREE We also transfected a lung cancer cell line that lacks RASSF1A expression with vectors containing RASSF1A complementary DNA to determine whether exogenous expression of RASSF1A would affect in vitro growth and in vivo tumorigenicity of this cell line.All statistical tests were two-sided. 11333291 2001
CUI: C0149925
Disease: Small cell carcinoma of lung
Small cell carcinoma of lung 		0.070 PosttranslationalModification disease BEFREE RASSF1A promoter hypermethylation was detected in 100% of SCLC, in 63% of NSCLC, in 64% of breast cancer lines, in 30% of primary NSCLCs, and in 49% of primary breast tumors but in none of the nonmalignant lung tissues. 11333291 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Promoter hypermethylation of the 5'CpG island of RASSF1A was detected in 4 of 4 (100%) xenografts, in 3 of 4 (75%) cell lines, and in 14 of 21 (66.7%) primary tumors but not in the normal nasopharyngeal epithelia. 11358799 2001
CUI: C2931822
Disease: Nasopharyngeal carcinoma
Nasopharyngeal carcinoma 		0.100 GeneticVariation disease BEFREE The high incidence of RASSF1A alterations suggest that it is the critical target gene on chromosome 3p21.3 involved in the development of NPC. 11358799 2001
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 Biomarker phenotype BEFREE The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. 11390984 2001